Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers.
Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers.
复制标题
DOI：
10.3389/fimmu.2023.1086006
复制
发表时间：
2023
影响因子：
7.3
通讯作者：
Crossland, Rachel E.
中科院分区：
文献类型：
--
作者：
Bojanic, Ines;Worel, Nina;Pacini, Carolina P.;Stary, Georg;Piekarska, Agnieszka;Flinn, Aisling M.;Schell, Kimberly J.;Gennery, Andrew R.;Knobler, Robert;Lacerda, Joao F.;Greinix, Hildegard T.;Pulanic, Drazen;Crossland, Rachel E.
关键词：
造血干细胞移植（HSCT）是治疗恶性血液病的首选方法。尽管移植前和移植后程序不断改进，但allo-HSCT的适用性受到危及生命的并发症的限制，如移植物抗宿主病（GvHD）、植入失败和机会性感染。体外循环血液置换术（ECP）用于治疗类固醇耐药GvHD，取得了显著成功。然而，驱动其免疫调节作用的分子机制，同时保持免疫功能，需要进一步了解。由于ECP是安全的，几乎没有显着的不良反应，它有可能在移植物抗宿主病的HSCT后治疗早期使用。因此，进一步了解ECP作用的免疫调节机制可能会证明在临床实践中更及时地使用ECP，以及识别使用ECP作为一线或先发制人的GvHD治疗的生物标志物。本综述旨在讨论ECP的技术方面和反应，审查ECP作为慢性GvHD的免疫调节治疗方式，包括对调节性T细胞和循环与组织驻留免疫细胞的影响，并考虑新出现的生物标志物对ECP反应的重要性。
Haematopoietic stem cell transplantation (HSCT) is the treatment of choice for malignant haematological diseases. Despite continuous improvements in pre- and post-transplantation procedures, the applicability of allo-HSCT is limited by life-threatening complications such as graft-versus-host disease (GvHD), engraftment failure, and opportunistic infections. Extracorporeal photopheresis (ECP) is used to treat steroid resistant GvHD with significant success. However, the molecular mechanisms driving its immunomodulatory action, whilst preserving immune function, require further understanding. As ECP is safe to administer with few significant adverse effects, it has the potential for earlier use in the post-HSCT treatment of GvHD. Thus, further understanding the immunomodulatory mechanisms of ECP action may justify more timely use in clinical practice, as well as identify biomarkers for using ECP as first line or pre-emptive GvHD therapy. This review aims to discuss technical aspects and response to ECP, review ECP as an immunomodulatory treatment modality for chronic GvHD including the effect on regulatory T cells and circulating vs. tissue-resident immune cells and consider the importance of emerging biomarkers for ECP response.
登录
查看更多内容
DOI：
10.5114/ceji.2017.67312
发表时间：
2017
期刊：
Central-European journal of immunology
影响因子：
--
作者：
Budde H;Berntsch U;Riggert J;Legler TJ
通讯作者：
Legler TJ
影响因子：
1.9
作者：
Bladon, John;Taylor, Peter
通讯作者：
Taylor, Peter
影响因子：
7.5
作者：
Belizaire, Roger;Kim, Haesook T.;Koreth, John
通讯作者：
Koreth, John
影响因子：
32.4
作者：
Chatila, Talal A.;Williams, Calvin B.
通讯作者：
Williams, Calvin B.
影响因子：
20.3
作者：
Alho, Ana C.;Kim, Haesook T.;Ritz, Jerome
通讯作者：
Ritz, Jerome